Ketotifen A review of its therapeutic efficacy in dermatological disorders

Clinical Immunotherapeutics

Volumn 5, Issue 5, 1996, Pages 400-411

  Markham, Anthony ^a   Goa, Karenl ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

KETOTIFEN;

ADULT; ATOPIC DERMATITIS; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; FOOD ALLERGY; HUMAN; MASTOCYTOSIS; NEUROFIBROMATOSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SKIN DISEASE; URTICARIA;

EID: 0029934570     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259336     Document Type: Article

References (72)

1. Esau S, del-Carpio J, Mariin JG. A comparison of the effects of ketotifen and clemastine on cutaneous and airway reactivity to histamine and allergen in atopic asthmatic subjects. J Allergy Clin Immunol 1984 Sep: 74 (3 Pt I ): 270-4
2. Phillips MJ. Meyrick Thomas RH. Moodley I. et al. A comparison of the /H vim effects of ketotifen. clemastine, chlorpheniramine and sodium cromoglycatc on histamine and allergen induced weals in human skin. Br J Clin Pharmacol 1983 Mar: 15: 277-86
3. Wang SS. Wang SR. Chiang BN. et al. Suppressive effects of oral ketotifen on skin responses to histamine. codeine, and allergen skin tests. Ann Allergy 1985 Jul: 55: 57-61
4. Mansfield LE, Taistra P, Santamauro J, et al. Inhibition oi'dermographia, histamine. and dextromethorphan skin tests by ketotifen. A possible effect on cutaneous vascular response to mediators. Ann Allergy 1989 Sep; 63: 201-6
5. Ciprandi G, Scordainaglia A, Ruffoni S, et al. Ketotifen treatment of adverse reactions to foods: clinical and immunological effects. Curr Med Res Opin 1986; 10: 346-50
6. Kondo N, Fukutomi O. KameyamaT. et al. Suppression of prolit'erative responses of lymphocytes to food antigens by an anti-allergic drug, ketotifen t'umarate. in patients with foodsensitive atopic dermatitis. Int Arch Allergy Immunol 1994 Mar; 103: 234-8
7. Furukawa-Nakayama F. Sakamoto T, Tamamori T. et al. Effect of anti-allergic drugs on CD23 expression in peripheral blood lymphocytes. Eur J Dermatol 1994 May; 4: 325-8
8. Takigawa M. Tamamori T, Horiguchi D, et al. Fce/CD23RII/ CD23-positive lymphocytes in atopic dermatitis. 1. Clin Exp Immunol 1991; 84: 275-82
9. Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992; 97 (3): 216-25
10. Huston DP. Bressler RB, Kaliner M. et al. Prevention of mastcell degranulation by ketotifen in patients with physical urticarias. Ann Intern Med 1986 Apr; 104: 507-10
11. DevillierP, Arnoux B. KeralyCL. et al. Inhibition of human and rabbit platelet activation by ketotifen. Fundam Clin Pharmacol 1990:4(1): 1-9
12. Konno S-i, Asano K, Okamoto K-i, et al. Inhibition of cytokine production from human peripheral blood leukocytes by antiallergic agents in vitro. Eur J Pharmacol 1994 Nov 3: 264: 265-8
13. Petrasch S, van Tits LJH, Motulsky HJ, et al. Effects of ketotifen on human lymphocytes in vitro and in vivo. Arzneimittel Forschung 1993 Äug; 43: 904-8
14. Michel MC. Polizzi S, Motulsky J. Inhibition of lymphocyte proliferation and activation by ketotifen and cyclosporin A |ahstract|. BrJ Pharmacol 1990 Apr: 99 Suppl.: 165P
15. Okayama Y. Benyon RC. Lowman MA, etal. In vitro effects of Hi-antihistamines on histamine and PGÖ2 release from mast cells of human lung, tonsil, and skin. Allergy 1994 Apr; 49: 246-53
16. Grant SM, Goa KL, Fitton A, c( al. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders (published erratum appears in Drugs 1991 Feb;4l(2):192|. Drugs 1990 Sep; 40:412-48
17. Nahe M. Miyagawa H. Agrawal DK. et al. The effect of ketotifen on eosinophils as measured at LTCa release and by chemotaxis. Allergy Proc 1991 Jul-Aug: 12: 267-71
18. Morita M, Tsuruta S, Mori KJ, et al. Ketotifen inhibits PAFinduced actin polymerization in a human eosinophilic leukaemia cell line, EoL-1. Eur RespirJ 1990 Nov; 3: 1173-8
19. Hossain M. Okubo Y, Sekiguchi M. Effects of various drugs (ketotifen, theophylline. FK506, cyclosporin A. staurosporine and herbimycin A) on eosinophil viability |abstract |. J Allergy Clin Immunol 1994 Jan; 93: 258
20. Kojima T. Ono A. Aoki T, ct al. Circulating 1CAM-I levels in children with atopic dermatitis. Ann Allergy 1994 Oct; 73: 351 -5
21. Azuma A. Effect of Zaditen (Rm) on atopic dermatitis. Assessment by peripheral eosinophil and serum ECP level |in Japanese]. Shinyaku to Rinsho 1992 Feb; 41: 440-50
22. Chung KF, Minette P, McCusker M. et al. Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in man. J Allergy Clin Immunol 1988Jun:81: 1192-8
23. Walker M, Harley R, Leroy EC. Ketotifen prevents skin fibrosis in tight skin mouse. J Rheumatol 1990 Jan; 17: 57-9
24. Grahnén A, Lönneho A, Beck O, et al. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos 1992 May; 13: 255-62
25. Schinidt-Redemann B, Brenneisen P, Schmidt-Redemann W. et al. The determination of pharmacokinetic parameters of ketotifen in steady state in young children. Int J Clin Pharmacol Ther Toxicol 1986 Sep; 24: 496-8
26. Kennedy OR. Metabolism and phannacokinetics of ketotifen in children. Res Clin Forum 1982:4: 17-20
27. Anzai T. Harada S. Nakanishi H, et al. Clinical evaluation of OLK (a single dose liquid container of ketotifen) on eczema/ dermatitis, urticaria and pruritus cutaneus [in Japanese!. Rinsho lyaku 1994; 10(6): 1355-70
28. Ando S, Aoki T, Yoshikawa K, et al. Effect of Zaditen (Rm) (ketotifen fumarate) on atopic dermatitis and chronic eczema. Relationship with eosinophil activity [in Japanese]. Shinryo to Shinyaku 1993; 30 (2): 363-73
29. Sergeev 1UV. Potekaev NS. Clinical efficacy and prospects in Zaditen (ketotifen) therapy of allergic dermatoses [in Russian]. Vestn Dermatol Venerol 1987; 4: 52-5
30. Sauer RR, Steigleder GK. Effect of ketotifen and oxatomide on histamine liberation due to exposure in cold urticaria [in German]. Z Hautkr 1983 Dec 15; 58: 1768-72
31. Moreno JN, Harfi HA. Cold urticaria in Saudi Arabia. Ann Allergy 1989 Oct; 63: 331-4
32. Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy 1989 Apr: 62: 322-5
33. McClean SP, Arreaza EE, Lett-Brown MA, et al. Refractory cholinergic urticaria successfully treated with ketotifen |see comments|. J Allergy Clin Immunol 1989 Apr; 83: 73K-4I
34. Taube KM, Wozniak KD, Lassig W. Ketotifen treatment of chronicurticaria. An open study of therapeutically difficult courses [in German|. Z Hautkr 1985 Dec 1;60: 1878,1881-2,1885
35. Sanjar S, Aoki S, Kristersson A, et al. Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea-pigs: the effect of anti-asthma drugs. Br J Pharmacol 1990 Apr; 99: 679-86
36. Si-Pierre JP. Kobric M. Rackham A. Effect of ketotifen treatment on cold-induced urticaria. Ann Allergy 1985 Dec; 55: 840-3
37. Phanuphak P. Locharenkul C. Double-blind, placebo-controlled study of ketotifen in chronic urticaria [abstract no. 2671. J Allergy Clin Imtnunol 1986: 77: 187
38. Yang WH. Drouin MA. Copeland D. et al. Double-blind multicenlre study of ketotifen (Zaditen) in chronic idiopathic urti caria |abstract]. J Allergy Clin Immunol 1991 Jan: 87: 224
39. Ishibashi Y. HaradaS. Kukitu A.etal. A clinical study of aslem i/ole (MJD-30) in treating chronic urticaria. A double blind, comparative study using ketotifen fumarate as a control drug (in Japanese!. Rinsho lyaku 1990 Aug; ft: 1623-38
40. Ishibashi Y. Harada S. Niimura M. et al. Clinical evaluation of KG-2413 (emedastine difumarate) on chronic urticaria by multicenter double-blind study. Comparative study between 2mg/day, 4mg/day. and ketotifen fumarate |in Japanese]. Rinsho lyaku I99()jan;ft: 141 59
41. Kukita A. Harada S. Okawara A. el al. Phase III study of WAL801CL(epinastine)on chronic urticaria. A double blind study in comparison with ketolifen fumarate |in Japanese|. Rinsho lyaku 1991: 7(101: 2303-20
42. Kukita A. Harada S. Yoshida H. et al. Phase III study of LAS-90 on chronic urticaria: double blind comparative study with ketotifen fumarate |in Japanese). Rinsho lyaku 1994: 10 (4): 895-912
43. Tuchinda M. Srimaruta N, Habanananda S. et al. Urticaria in Thai children. Asian Pac J Allergy Immunol 198ft J un: 4: 41 -5
44. Martine/ FV. Contreras FJ. Cazana JML, et al. A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). J Invest Allergol Clin Immunol 1992 Sep-Oct: 2: 258-ft2
45. Corrias A. Rossi G. Nardi MG. Ketotifen in the treatment of pédiatrie atopic eczema |in Italian]. Pedialr Med Chir I9S5 Nov-Dec:7:881-5
46. Falk FS. Ketotifen in the treatment ol atopic dermatitis. Results of a double blind study. Riv Fur Sei Med Farmacol 1993 Mar-Apr: 15: 63-6
47. Yoshida H. Niimura M. Ueda H. et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy 1989 Jtin;62: 507-12
48. Kaplan AP. Buckley RH. Malllew KP. Allergic skin disorders. JAMA 1987; 258: 2900-9
49. likura Y. Naspit/ CK. Mikawa H. el al. Prevention of asthma by kelotifen in infants with atopic dermatitis. Ann Allergy 1992 Mar: 68: 233-6
50. likura Y, Baba M. Mikawa H. et al. A double blind study ol the effectiveness of ketotifen in preventing the development of asthma in atopic dermatitis patients |in Japanese]. Arerugi 1991 Feb;4(): 132-40
51. Bustos GJ. Bustos D. Bustos GJ. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Fxp Allergy 199,5 Jun: 25: 568-73
52. Hiratani M. ItoS. MutoK.etal. Efficacy ol kelotifen in subjects with food allergy. J Allergy Clin Immunol 1987; 79: 185
53. Molkhou P. Dupont C. Ketotifen in prevenlion and therapy of food allergy. Ann Allergy 1987 Nov; 59 (5 Pt II): 187-93
54. Boner AL. Richelli C. Anlolini I, el al. The efficacy of ketolifen in a controlled double-blind study in patients with food allergy. Ann Allergy 1986 Jul; 57: ftl-4
55. Czarne(/ki BM. A duiiblc'-hlind cross-over study of the cl'fecl of ketotifen in urticaria pimnentosa. Dermatolosica 19X3; 16ft: 44-7
56. Keltelhul BV. Berkebile C. Bradley D. et al. A double-blind, placebo-controlled, crossover trial of kelotifen versus hydroxy/inc in the treatment of pédiatrie mastocytosis [see comments|. J Allergy Clin Immunol 1989 May;'8.3: 866 7(1
57. Riccardi VM. Mast-cell stabilization to decrease neurofibroma growth. Preliininary experience with ketotifen. Arch Derniatol 19X7 Ang; 12.1: KII1-6
58. Von Haustein U F. Ketotifen inhibits urticaria and tumor progression in neurofibromatosis ]in German). Derniatol Monatsschr 1989; 175:581-4
59. Kawamura K. Jono M. Katsuragi M. el al. A case of neurofihromatosis with occlusion of multiple cerebral artery. Moyamoya phenomenon and scoliosis (in Japanese). No To Shinkei 1994 Dec: 46: 1163-8
60. Gruber BL. Kaufman LD. Kelotifen-induced remission in progressive early diffuse scleroderma: evidence for the role of mast cells in disease palhogenesis. Am .1 Med 1990 Sep: 89: 392-5
61. Fain O. Sitbon M, Feton N. et al. Treatment of systemic scleroderma with ketotifen. Results after one \ear |in French] |abstract]. Rev Med Interne 1992 Dec: 13: 449
62. Gruher BL. Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991 Mar: 34: 362-6
63. Maclay WR Crowder D. Spiro S. et al. Postmarkeling surveilance: practical experience with ketotifen. BM.I 19X4; 2XX: 911-4
64. ft4. Humbert H. C'abiac M-D. Bosshard H. In vitro-in \ivo correlation of a modified-release oral form of ketotifen: in \itrn dissolution rate spécification. J Pharm Sei 1994 Feb: X3: 131-6
65. Saunders R. editor. New ethlcals compendium. Auckland: AD1S Press. 1989:980-981
66. Le Blaye I. Donatini B. Hall M. et al. Acute ketolilcn overdosage. A re\iew of present clinical experience. Drim Sal 1992 Sep-Oct: 7: 3X7-92
67. Bolognia J. Braverman IM. Skin manifestations of internal disease. In: Wilson JD. Graunwuld E. Isselbacher KJ. et al., editors. Harrison s principles of internal medicine. 12thed. v. 1. New York: McGraw-Hill. 1991: 322-38
68. Ormerod AD. Urticaria. Recognition, causes and treatment. Drugs 1994 Nov: 48: 717-31)'
69. Marks J. Raw lins MD. Skin diseases. In: Speight TM. editor. Drug treatment: principles and practice of clinical pharmacology and therapeutics. 3rd ed. Auckland: AD1S Press. 19X7: 439-80
70. Hanifin JM. Pharmacological abnormalities in atopic dermatitis. Allergy 19X9:44: 41-6
71. Lawley TJ. Swerlick RA. Ec/ema. psoriasis, cutaneous infections, acne, and other common skin disorders. In: Wilson JD. Braunwald E. Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. I2lhcd.v. I. New York: McGraw Hill. 1991: 307-12
72. Meyer LJ. Drug therapy for neurotibroniatosis'.' Arch Oermatol 1993 May; 129: 625-6